J.M.H. Raats
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.M.H. Raats.
BioEssays | 2000
Richard J. Rodenburg; J.M.H. Raats; G.J.M. Pruijn; W.J.W. van Venrooij
Systemic autoimmune diseases are characterized by the production of antibodies against a broad range of self‐antigens. Recent evidence indicates that the majority of these autoantigens are modified in various ways during cell death. This has led to the hypothesis that the primary immune response in the development of autoimmunity is directed to components of the dying cell. In this article, we summarize data on the modification of autoantigens during cell death and the possible consequences of this for autoimmunity. BioEssays 22:627–636, 2000.
Cell Death & Differentiation | 2000
Winfried G. J. Degen; G.J.M. Pruijn; J.M.H. Raats; W.J.W. van Venrooij
Autoimmune diseases are frequently characterized by the presence of autoantibodies directed against nucleic acid-protein complexes present in the nucleus of the cell. The mechanisms by which these autoantigenic molecules escape immunological tolerance are largely unknown, although a number of recent observations suggest that modified self-proteins generated during apoptosis may play an important role in the development of autoimmunity. It has been hypothesized that the recognition of these modified self-proteins by the immune system may promote autoantibody production. While apoptosis is specifically characterized by posttranslational modification of proteins, recent findings also show that nucleic acids are modified. This review summarizes the specific cleavages of some of these key nucleic acids, i.e. chromosomal DNA, ribosomal RNA and small structural RNAs (U1 snRNA, Y RNA), in apoptotic cells. Cell Death and Differentiation (2000) 7, 616–627
Arthritis Research & Therapy | 2001
Tj Smeets; Erik R. Vossenaar; Mc Kraan; Wam van Mansum; J.M.H. Raats; W.J.W. van Venrooij; Pp Tak
The presence of autoantibodies directed to citrulli-nated antigens in serum is highly specific for RA. The aim of this study was to compare anti-CCP concentrations in paired serum/SF samples of patients with RA and to investigate whether this is associated with the expression of citrullinated antigens in RA synovium and to study the nature of these antigens.
Arthritis Research & Therapy | 2001
J.M.H. Raats; Winfried G. J. Degen; S. G. H. Litjens; Ibrahim Bulduk; Gijs Mans; E Wijnen; S Zampieri; Will Roeffen; F.H.J. van den Hoogen; W.J.W. van Venrooij
One important property of the immune system is its ability to discriminate between self and non-self antigens. The unresponsiveness of the immune system to self-antigens is called self-tolerance, loss of this property results in immune reactions against own or autologous antigens. Such reactions often are associated with an autoimmune disorder and eventually may contribute to clinical manifestations. The humoral immune response plays a crucial role in the onset of autoimmunity, and it is a general observation that autoimmune diseases are associated with distinct profiles of autoantibodies. During the last five years there has been a growing interest in finding possible connections between apoptosis and autoimmunity. It has been hypothesized that the recognition, uptake, processing, or presentation of modified self-antigens may promote autoantibody production. At present, many autoantigens have been found that are modified (i.e. cleaved, phosphorylated or dephosphorylated) during apoptosis. Using autoimmune patient sera in immunoprecipitation and Western blotting assays with cell extracts derived from non-apoptotic and apotptic cells, we identified sera reactivities specific for (novel) modifications of autoantigens. In this paper we give an overview of our studies on human recombinant autoantibodies derived from patients suffering from rheumatic diseases. Furthermore, we describe the generation of recombinant chicken antibodies specific for human autoantigens that will also be used to study these antigens and (apoptotic) modifications thereof in more detail. We selected human recombinant antibodies from patient phage display scFv combinatorial antibody libraries (complexity of 107 or higher) derived from peripheral blood or bone marrow lymphocytes of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma (SSc). Next to the human patient libraries we also used chicken libraries made from spleens of animals immunized with 7 human (auto)antigens simultaneously. Screening of both patient and animal derived libraries with recombinant or purified autoantigens resulted in several recombinant monoclonal human and chicken (auto)-antibodies. From our SLE patient libraries, autoantibodies against U1snRNP components U1-A, U1-C, U1-70k and U1-RNA were selected. Moreover, from our SLE libraries we selected anti Ro52 and anti ribosomal P protein antibodies, and from both our SLE and scleroderma libraries we selected anti-La and anti a-fodrine recombinant antibodies. From our RA patient libraries antibodies specific for RA related peptides were obtained. All human scFv clones obtained were characterized by ELISA, immunoprecipitation assays, western blotting, epitope mapping and of some clones the affinities were measured and competition experiments with patient sera were performed. Sequence analysis was performed to study the germline usage. All chicken clones were sequenced and analyzed by LIA, Western blot and ELISA. We will discuss characteristics of some of the selected scFvs i.e. epitope mapping, germline gene usage, and competition experiments with patient sera. The phage autoantibodies selected from autoimmune patient libraries were also analyzed for their specificity for (apoptotically) modified forms of their target autoantigens by Western blotting and immunprecipitation assays using apoptotic cell-extracts. Some anti-La, anti-70K and anti-RA peptide scFvs recognized (apoptotically)-modified forms of their target antigens.
RNA | 2006
Tim J.M. Welting; F.M.A. Peters; S.M.M. Hensen; N.L. van Doorn; B.J. Kikkert; J.M.H. Raats; W.J.W. van Venrooij; G.J.M. Pruijn
Archive | 1997
Venrooij Waltherus Jacobus Wilhelmus Van; Gerardus Antonius Schellekens; J.M.H. Raats; R.M.A. Hoet
Molecular Immunology | 1998
R.M.A. Hoet; J.M.H. Raats; R.M.T. de Wildt; Hélène Dumortier; S.H. Muller; F.H.J. van den Hoogen; W.J.W. van Venrooij
Archive | 1997
Waltherus Jacobus Wilhelmus Van Venrooij; J.M.H. Raats; R.M.A. Hoet; Gerardus Antonius Schellekens
Marine and Freshwater Research | 2007
Danielle Hof; G.J.M. Pruijn; W.J.W. van Venrooij; J.M.H. Raats
Archive | 2006
Waltherus Jacobus Wilhelmus Van Venrooij; Gerardus Antonius Schellekens; J.M.H. Raats; R.M.A. Hoet